Daily Cardiology Research Analysis
Three impactful cardiology studies stood out: (1) flexible mesh nanoelectronics revealed arrhythmogenic automaticity in transplanted human iPSC-derived cardiomyocytes and a self-assembling peptide (RADA16) mitigated it; (2) intravascular imaging guidance during PCI of severely calcified lesions was associated with lower 1-year target vessel failure versus angiography alone; (3) neutrophil-to-lymphocyte ratio (≥4) provided robust risk stratification in myocarditis, especially with preserved LVEF.
Summary
Three impactful cardiology studies stood out: (1) flexible mesh nanoelectronics revealed arrhythmogenic automaticity in transplanted human iPSC-derived cardiomyocytes and a self-assembling peptide (RADA16) mitigated it; (2) intravascular imaging guidance during PCI of severely calcified lesions was associated with lower 1-year target vessel failure versus angiography alone; (3) neutrophil-to-lymphocyte ratio (≥4) provided robust risk stratification in myocarditis, especially with preserved LVEF.
Research Themes
- Mechanistic safety insights for cardiac regeneration using nanoelectronics and biomaterials
- Precision interventional cardiology with intravascular imaging guidance in calcified PCI
- Inflammation-based risk stratification in myocarditis across the LVEF spectrum
Selected Articles
1. Flexible nanoelectronics reveal arrhythmogenesis in transplanted human cardiomyocytes.
Using flexible mesh nanoelectronics in beating rat hearts, the authors directly recorded fibrillation and automaticity from transplanted human iPSC-derived cardiomyocytes. The self-assembling peptide RADA16 promoted maturation and vascularization while markedly suppressing arrhythmogenic automaticity, highlighting a combined bioelectronic–biomaterial strategy to improve cardiac cell therapy safety.
Impact: This study introduces an in vivo nanoelectronic platform to interrogate and mitigate arrhythmias from grafted human cardiomyocytes, addressing a key safety barrier in cardiac cell therapy. The mechanistic insight and a clinically approved peptide intervention offer a translational path.
Clinical Implications: Highlights an approach to reduce graft-related arrhythmias by conditioning the graft microenvironment (RADA16) and monitoring with implantable nanoelectronics. May inform peri-transplant strategies and safety endpoints for human cardiac cell therapy trials.
Key Findings
- Flexible mesh nanoelectronics detected fibrillation and spontaneous activity from transplanted hiPSC-CMs in vivo.
- RADA16 accelerated adult-like gene expression, enhanced sarcomere organization, and improved vascularization at the graft site.
- RADA16 markedly reduced arrhythmogenic automaticity in transplanted hiPSC-CMs.
Methodological Strengths
- Innovative in vivo electrophysiological mapping with flexible mesh nanoelectronics in a beating heart.
- Multimodal assessment (transcriptomic maturation, myofibrillar structure, vascularization) with a clinically approved biomaterial.
Limitations
- Preclinical animal model; human clinical efficacy and long-term safety remain untested.
- Quantitative arrhythmia burden and durability beyond the study window were not fully detailed.
Future Directions: Validate nanoelectronic monitoring and RADA16 conditioning in large-animal models, define dosing/timing, and develop clinical-grade sensors to monitor graft electrophysiology in first-in-human trials.
The transplantation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offers a potential treatment for heart failure, but arrhythmogenic automaticity can arise from these transplanted cells. In this study, we investigated the effects of RADA16, a clinically approved self-assembling peptide that forms nanofibers after injection, on the vascularization, myofibril structure, and electrophysiological adaptation of hiPSC-CMs transplanted into rat hearts. RADA16 accelerated the transition of hiPSC-CMs toward adultlike gene expression profiles, enhanced sarcomere organization, and improved vascularization in the transplanted site. Flexible mesh nanoelectronics revealed fibrillation of transplanted hiPSC-CMs within the beating recipient heart, and RADA16 drastically reduced the automaticity of
2. Intravascular Imaging vs Angiography Guidance for PCI of Severely Calcified Lesions: The ECLIPSE Trial.
In this large randomized trial cohort of severely calcified lesions, intravascular imaging guidance (OCT/IVUS) was associated with a significantly lower 1-year target vessel failure versus angiography alone (adjusted HR 0.74). Benefits were consistent irrespective of vessel preparation strategy (orbital atherectomy or balloon angioplasty).
Impact: Demonstrates outcome benefit of IVI guidance in a challenging real-world population (severely calcified lesions), informing procedural standards and training priorities.
Clinical Implications: Supports routine consideration of OCT/IVUS guidance for PCI in severely calcified lesions to reduce 1-year target vessel failure, regardless of vessel preparation technique.
Key Findings
- Among 2,005 patients with severely calcified lesions, IVI guidance was used in 62.1% and angiography alone in 37.9%.
- 1-year target vessel failure was lower with IVI versus angiography (9.3% vs 13.2%; adjusted HR 0.74; 95% CI 0.56–0.97; P=0.03).
- Benefit of IVI guidance was consistent irrespective of orbital atherectomy or balloon angioplasty vessel preparation.
Methodological Strengths
- Large randomized trial framework with prespecified 1-year clinical endpoint (TVF).
- Adjusted analyses and consistency across different vessel preparation strategies.
Limitations
- Use of IVI was not randomized; potential selection and confounding biases remain.
- Follow-up limited to 1 year; generalizability beyond severely calcified lesions requires caution.
Future Directions: Randomized allocation of IVI guidance, cost-effectiveness analyses, and extension to broader lesion subsets and longer-term outcomes.
BACKGROUND: Few studies have examined whether intravascular imaging (IVI) guidance during percutaneous coronary intervention (PCI) of calcified lesions improves clinical outcomes. OBJECTIVES: The aim of this study was to determine from a large-scale randomized trial of PCI in severely calcified lesions whether IVI guidance improves event-free survival. METHODS: In the ECLIPSE (Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting Stents) trial, 2,005 patients with severely calcified lesions were randomized to orbital atherectomy (OA) vs balloon angioplasty (BA) prior to drug-eluting stent placement. IVI with optical coherence tomography or intravascular ultrasound (IVUS) was allowed at operator discretion. The primary clinical outcome was the 1-year rate of target vessel failure (TVF. RESULTS: IVI guidance was used in 1,246 of 2,005 patients (62.1%), including optical coherence tomography in 819 and/or IVUS in 513, while 759 of 2,005 patients (37.9%) underwent PCI with angiographic guidance alone. Median follow-up duration was 365 days (Q1-Q3: 365-365 days). The 1-year Kaplan-Meier estimated rate of TVF was lower among patients with IVI guidance compared with angiographic guidance alone (9.3% vs 13.2%; adjusted HR: 0.74; 95% CI: 0.56-0.97; P = 0.03). The effect of IVI guidance was consistent in patients randomized to OA vs BA (P
3. Neutrophil-to-lymphocyte ratio for risk stratification in acute myocarditis across the left ventricular ejection fraction spectrum.
In a multicentre cohort of 1,150 biopsy/CMR-proven myocarditis cases, an NLR ≥4 provided prognostic discrimination comparable to traditional high-risk definitions and outperformed them in patients with preserved LVEF (AUC 0.73 vs 0.52). NLR is a simple, accessible biomarker to aid risk stratification across the LVEF spectrum.
Impact: Provides an immediately implementable, low-cost biomarker-based tool to refine risk stratification in myocarditis, addressing a gap particularly in patients with preserved LVEF.
Clinical Implications: Incorporating NLR (threshold ≥4) into initial assessment may improve triage, monitoring intensity, and follow-up planning, especially when LVEF is preserved and traditional definitions underperform.
Key Findings
- Among 1,150 biopsy/CMR-proven cases with median 228-week follow-up, 5.2% reached death or transplant.
- NLR had AUC 0.72 overall, comparable to complicated/high-risk definitions (AUC 0.73) and superior to fulminant classification (AUC 0.62).
- In preserved LVEF (≥50%), NLR achieved AUC 0.73 versus 0.52 for both complicated and high-risk definitions.
Methodological Strengths
- Large international multicentre cohort with biopsy/CMR-confirmed myocarditis.
- Direct comparison of NLR against established high-risk definitions and stratified analysis by LVEF.
Limitations
- Observational design with potential residual confounding and centre heterogeneity.
- Event rates were relatively low, and external validation of the NLR threshold may be needed.
Future Directions: Prospective validation of NLR thresholds, integration with imaging/biomarker panels, and evaluation of NLR-guided management pathways.
AIMS: Acute myocarditis (AM) is a heterogeneous clinical condition. Several classification models have been proposed to predict adverse clinical outcomes, but risk stratification remains challenging, particularly for patients presenting with preserved left ventricular ejection fraction (LVEF). Neutrophil-to-lymphocyte ratio (NLR) is a useful tool for risk stratification in patients with AM. This study aimed to compare the predictive accuracy of available risk stratification models, including NLR, for identifying patients with AM at increased risk of adverse events. METHODS AND RESULTS: The study included 1150 patients with biopsy- or cardiac magnetic resonance (CMR)-proven AM from 10 hospitals in six countries. Baseline clinical, laboratory, echocardiographic and CMR data, and clinical outcomes, were collected. The population was divided into four groups based on published models of high-risk AM (complicated, fulminant, high-risk, and NLR ≥4). The primary outcome was all-cause mortality and heart transplantation. During a median follow-up of 228 weeks (interquartile range 114-339), 63 events occurred in 60 patients (5.2%) who experienced the primary outcome. NLR (area under the curve [AUC] 0.72) performed similarly to complicated (AUC 0.73) and high-risk definitions (AUC 0.73) for the prediction of adverse events, while the fulminant classification showed significantly inferior predictive accuracy (AUC 0.62, p = 0.02). Moreover, among patients with preserved LVEF (≥50%) at presentation, NLR showed superior prognostic value (AUC 0.73; complicated: 0.52, p = 0.001; high-risk: 0.52, p = 0.002). Multivariable analysis confirmed that each classification was independently associated with the primary outcome. However, the NLR model showed better predictive performance compared to the other models among patients with LVEF ≥50%. CONCLUSIONS: While traditional definitions of high-risk AM remain valuable, NLR ≥4 is a simple and cost-effective marker that aids in risk stratification. NLR ≥4 is particularly robust in patients with preserved LVEF, supporting its use across the LVEF spectrum.